insulin glargine+ glulisine + NPH + Regular insulin
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diabetic Ketoacidosis
Conditions
Diabetic Ketoacidosis
Trial Timeline
Dec 1, 2007 → Aug 1, 2008
NCT ID
NCT00590044About insulin glargine+ glulisine + NPH + Regular insulin
insulin glargine+ glulisine + NPH + Regular insulin is a approved stage product being developed by Sanofi for Diabetic Ketoacidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00590044. Target conditions include Diabetic Ketoacidosis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00590044 | Approved | Completed |
Competing Products
20 competing products in Diabetic Ketoacidosis